Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 50 and up Men only

Tamsulosin With or Without Tadalafil for a Trial Without Catheter After Acute Urinary Retention

Official title: Tamsulosin With Versus Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia: A Prospective Double-Blind Randomized Trial

Run by Beni-Suef University · NCT07654413 · Data updated 2026-11-12

This study tests whether adding tadalafil to tamsulosin helps men with a first episode of acute urinary retention due to enlarged prostate pass urine without needing a catheter.

More Benign Prostatic Hyperplasia trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages50 Years and up
SexMen only
Enrollment320 (estimated)
SponsorBeni-Suef University
Academic / other
Locations1 site (Banī Suwayf, Beni Suweif Governorate)
StatusRecruiting
StartedJune 8, 2026
Main results expectedNovember 2027
Study endsDecember 2027
Registry record updatedJune 17, 2026
Trial IDNCT07654413 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are men aged 50+ with a first episode of spontaneous painful acute urinary retention due to presumed BPH, who had successful catheter drainage and meet all eligibility criteria.

Probably not a fit

Patients who do not respond to the trial medications or who have contraindications or non-BPH causes of retention may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 4, randomized trial compares tamsulosin alone versus tamsulosin plus tadalafil in men 50 and older who have had acute urinary retention due to benign prostatic obstruction. After initial catheter drainage, participants start their study medications within 24 hours and attempt to void without a catheter by day 7; a second trial without catheter may occur on day 14 if the first attempt fails. The primary outcome is catheter-free success by day 14, with follow-up for recurrent retention. The study is conducted at Beni-Suef University Hospital in Egypt and uses a tadalafil/placebo control to determine if combination therapy improves TWOC outcomes.

Why it matters

Potential benefit: If successful, treatment could increase the chances of avoiding long-term catheter use after acute urinary retention.

How similar studies have gone: Prior studies in BPH-related voiding symptoms have explored combination therapies, but this exact TWOC-focused approach is relatively novel and has limited prior success data.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male patient aged 50 years or older.
* First episode of spontaneous painful acute urinary retention.
* Successful urethral catheterization at presentation.
* Drained urine volume at presentation of at least 300 mL.
* Clinical impression of benign prostatic obstruction or benign prostatic hyperplasia based on history, digital rectal examination, and/or ultrasound evidence of enlarged prostate.
* Ability to provide written informed consent.

Exclusion Criteria:

* Previous episode of acute urinary retention.
* Chronic painless urinary retention phenotype.
* Active urinary tract infection or sepsis.
* Gross hematuria with clot retention.
* Suspected or known urethral stricture.
* Neurogenic bladder or major neurologic disease affecting voiding.
* History of prostate cancer or bladder cancer.
* Previous prostate surgery.
* Current use of nitrates or guanylate cyclase stimulators.
* Contraindication to tadalafil or tamsulosin.
* Severe hypotension or unstable cardiovascular disease.
* Severe renal impairment.
* Severe hepatic impairment.
* Current or recent use of phosphodiesterase type 5 inhibitors before enrollment.

Where it's running

  • Department of Urology- Beni-Suef University Hospitals
    Banī Suwayf, Beni Suweif Governorate, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.